Edmund K. Waller

This study identifies immune programs linked to leuprolide-associated cardiovascular risk in prostate cancer patients through spatial transcriptomic and immune-stromal profiling.

The paper identifies and characterizes VIP-R antagonists with high-affinity and potent anti-leukemia activity through in silico screening, in vitro testing, and in vivo validation.

This study shows that VPAC2 receptor signaling in pancreatic cancer cells promotes tumor growth and reduces immunogenicity, suggesting it as a therapeutic target.